China Pharma Holdings, Inc. Announces Record 2007 Year E...(cal years 2007 and 2006 respectively wit...)

Date:3/31/2008

cal years 2007 and 2006, respectively, with the slight reduction being primarily due to an increase of sales and marketing expenses. Diluted EPS for the fiscal year ended December 31, 2007 were $0.34 compared to $0.25 for 2006. The weighted average numbers of shares outstanding to calculate the diluted earnings per share were 37.3 million and 34.7 million, respectively.

Balance Sheet and Cash Flow Discussion

On December 31, 2007, the Company had $1.8 million in cash and equivalents and stockholders' equity of $39.8 million as compared with stockholders' equity of$20.9 million on December 31, 2006. Net cash from operations was $2.8 million for the twelve months ended December 31, 2007, as compared with net cash from operations of negative $1.7 million during 2006.

Total accounts receivable, less an allowance for doubtful accounts, was $18.6 million on December 31, 2007 as compared to $12.1 million on December 31, 2006. The increase in accounts receivable was due primarily to substantially higher revenues. The Company has had a good track record of customer collections since inception.

"We are very pleased to report another year of record revenue and net income. The Company performed well both in terms of financial performance and execution of our key business strategies. Our diversified portfolio and development strategy focused on therapeutics targeting high mortality and high population diseases enabled us to deliver a strong financial performance in 2007. Additionally, our investment in marketing has proven to be successful and we anticipate further benefits in 2008. The organic growth of our existing portfolio was due primarily to the expansion of our distribution network and increased market penetration. We believe that we have put in place the operating foundation and growth strategies which will enable us to sustain our growth and maintain our position as a leading generic drug company in China," Ms. Li concluded.

Revenue Gui
'/>"/>

SOURCE China Pharma Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch